Singapore's research agency and Duke-National University of Singapore have signed an agreement to collaborate with U.S. biotech Visterra on getting a promising treatment against dengue fever to the clinical-trial stage.
Singapore, like other Asian countries looking to woo pharmaceutical manufacturers, is moving quickly to meet increasing demand for high-quality water required by strict regulations in the U.S. and European Union.
In a deal spanning three continents, Asia's Strides Arcolab is paying nearly $300 million for the Australian generics business of Africa's Aspen Pharmacare Holdings. The deal also includes some branded drugs.
Indonesia's Kalbe Farma is making this year an expansion year as it moves beyond its shores and into Singapore and Thailand and their over-the-counter drug markets as a regional trade pact looks set to start at the end of the year. It also has corporate eyes set on even more countries, with a focus on West Africa.
Singapore government-controlled investment group Temasek has invested more than half a million dollars in Ranbaxy buyer Sun Pharmaceutical as well as other Indian drugmakers.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.
The buzz around biotech in Asia has centered on friends and family bootstrap operations in China, local investor support in Taiwan and onto more formal state-backed incubation efforts in Japan, South Korea and Singapore along with boutique venture capital firms and investment arms of multinationals such as Eli Lilly Ventures.
Sigma-Aldrich formally opened its Asia-Pacific headquarters in Singapore on Friday, the latest major supplier to pharmaceutical manufacturers and research institutions in Asia to stake out a base in the wealth city-state that has seen an explosion in state-of-the-art manufacturing operations.
A team of investigators from Duke and the NUS Graduate Medical School in Singapore says they've come up with a novel one-two punch directed against mutant RAS that they believe could have broad potential in fighting cancers.